TCGA-S3-AA15-01A-11R-A41B-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 18
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.490
- INFLAMMATORY_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- WNT_BETA_CATENIN_SIGNALING+0.360
- KRAS_SIGNALING_UP+0.350
- ANGIOGENESIS+0.340
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- PROTEIN_SECRETION-0.500
- ESTROGEN_RESPONSE_EARLY-0.460
- OXIDATIVE_PHOSPHORYLATION-0.370
- ESTROGEN_RESPONSE_LATE-0.330
- PEROXISOME-0.320
- FATTY_ACID_METABOLISM-0.290
- MYC_TARGETS_V1-0.280
- ANDROGEN_RESPONSE-0.210
- DNA_REPAIR-0.190
- TGF_BETA_SIGNALING-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A3XY-01A-11R-A239-07 | — | D | 0.891 |
| 2 | TCGA-AC-A8OQ-01A-11R-A41B-07 | — | D | 0.879 |
| 3 | TCGA-EW-A3U0-01A-11R-A22K-07 | — | D | 0.862 |
| 4 | TCGA-E2-A1LH-01A-11R-A14D-07 | — | E | 0.853 |
| 5 | R83 | — | — | 0.829 |
| 6 | X41226e40.d143.43b1.ac92.023809990077 | — | cohortA1 | 0.827 |
| 7 | SRR25617829 | — | D | 0.825 |
| 8 | TCGA-E2-A1LE-01A-12R-A19W-07 | — | D | 0.821 |
| 9 | TCGA-AC-A3W5-01A-11R-A22K-07 | — | D | 0.816 |
| 10 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |